仅对制药厂、医药研发公司、医药研究所、医院提供信息服务,不对个人提供信息服务!

Due to the shortage of foreign protective equipment, we have cooperated with EU CE certification / FDA registered manufacturers to open green channels to ensure the supply of protective equipment (masks, disinfectants, etc.)!

类别

搜索

地點

訂閱此搜索

191.10 Dollar US$

药品名称:Revolade 25 mg 14 tab药品简介:治疗适应症Revolade适用于自诊断后持续6个月或更长时间且对其他治疗(例如皮质类固醇,免疫球蛋白)无效的1岁及以上的原发性免疫性血小板减少症(ITP)的患者的治疗。在患有慢性丙型肝炎病毒(HCV)感染的成年患者中,应发生革命性反应,以治疗血小板减少症,其中血小板减少症的程度是阻止其开始或限制维持最佳干扰素疗法的主要因素。在患有获得性严重再生障碍性贫血(SAA)的成年患者中出现了恶变,这些患者要么对先前的免疫抑制治疗无效,要么经过严格的预处理,不适合进行造血干细胞移植药品通用名:Eltrombopag厂商:NOVARTIS剂型:片...

· 十二月 27, 2019
了解卖家

【商品名称】乐托品【通用名称】0.05%硫酸阿托品【规  格】5ml/盒【生产企业】五福化学制药有限公司【原 产 地】台湾【储存方法】请于25°以下阴凉干燥处储存,请勿吞食。

· 二月 1, 2020
了解卖家

New Drug Application (NDA): 211230Company: JAZZTreatment for: Narcolepsy, Obstructive Sleep Apnea/Hypopnea SyndromeDate of Approval:03/20/2019DrugName:SUNOSIActive Ingredients:SOLRIAMFETOL HYDROCHLORIDEStrength:EQ 75MG BASEPackage:100 BottlesDosage Form:TABLETDosage Route:ORALTE Code:...

· 五月 12, 2020
了解卖家

New Drug Application (NDA): 211230Company: JAZZTreatment for: Narcolepsy, Obstructive Sleep Apnea/Hypopnea SyndromeDate of Approval:03/20/2019DrugName:SUNOSIActive Ingredients:SOLRIAMFETOL HYDROCHLORIDEStrength:EQ 75MG BASEPackage:30 BottlesDosage Form:TABLETDosage Route:ORALTE Code:N...

· 五月 12, 2020
了解卖家

New Drug Application (NDA): 211371Company: SAGE THERAPTreatment for: Postpartum DepressionDate of Approval:03/19/2019DrugName:ZULRESSOActive Ingredients:BREXANOLONEStrength:100MG/20ML (5MG/ML)Dosage Form:SOLUTIONDosage Route:INTRAVENOUSTE Code:NoneRLD:YesRS:YesNDC:72152-547-20Start Ma...

· 五月 12, 2020
了解卖家

New Drug Application (NDA): 208259Company: AERIE PHARMS INCTreatment for: Glaucoma (Open Angle), Intraocular HypertensionDate of Approval:03/12/2019DrugName:ROCKLATANActive Ingredients:LATANOPROST; NETARSUDIL DIMESYLATEStrength:0.005%;EQ 0.02% BASEDosage Form:SOLUTION/DROPSDosage Rout...

· 五月 11, 2020
了解卖家

Biologic License Application (BLA): 761081Company: PFIZER INCTreatment for: Breast Cancer, Gastric CancerDate of Approval:03/11/2019DrugName:TRAZIMERAActive Ingredients:TRASTUZUMAB-QYYPStrength:420MGDosage Form:INJECTABLEDosage Route:INJECTIONTE Code:NoneRLD:NoRS:NoNDC:0069-0305-01Start Ma...

· 五月 11, 2020
了解卖家

New Drug Application (NDA): 211243Company: JANSSEN PHARMSTreatment for: Treatment-Resistant DepressionDate of Approval:03/05/2019DrugName:SPRAVATOActive Ingredients:ESKETAMINE HYDROCHLORIDEStrength:EQ 28MG BASE  84mgDosage Form:SPRAYDosage Route:NASALTE Code:NoneRLD:YesRS:YesNDC:...

· 五月 11, 2020
了解卖家

New Drug Application (NDA): 211243Company: JANSSEN PHARMSTreatment for: Treatment-Resistant DepressionDate of Approval:03/05/2019DrugName:SPRAVATOActive Ingredients:ESKETAMINE HYDROCHLORIDEStrength:EQ 28MG BASE  56mgDosage Form:SPRAYDosage Route:NASALTE Code:NoneRLD:YesRS:YesNDC:...

· 五月 11, 2020
了解卖家

New Drug Application (NDA): 212038Company: PURDUE PHARMA LPTreatment for: Attention-Deficit / Hyperactivity DisorderDate of Approval:02/27/2019DrugName:ADHANSIA XRActive Ingredients:METHYLPHENIDATE HYDROCHLORIDEStrength:85MGDosage Form:CAPSULE, EXTENDED RELEASEDosage Route:ORALTE Code...

· 五月 11, 2020
了解卖家

New Drug Application (NDA): 212038Company: PURDUE PHARMA LPTreatment for: Attention-Deficit / Hyperactivity DisorderDate of Approval:02/27/2019DrugName:ADHANSIA XRActive Ingredients:METHYLPHENIDATE HYDROCHLORIDEStrength:70MGDosage Form:CAPSULE, EXTENDED RELEASEDosage Route:ORALTE Code...

· 五月 11, 2020
了解卖家

New Drug Application (NDA): 212038Company: PURDUE PHARMA LPTreatment for: Attention-Deficit / Hyperactivity DisorderDate of Approval:02/27/2019DrugName:ADHANSIA XRActive Ingredients:METHYLPHENIDATE HYDROCHLORIDEStrength:55MGDosage Form:CAPSULE, EXTENDED RELEASEDosage Route:ORALTE Code...

· 五月 11, 2020

因国外防护用品短缺,特与拥有欧盟CE认证/FDA注册厂家合作,开通绿色通道,保证防护用品(口罩、消毒液等)供给!

Top
Online chat
Login to start chatting Sign in